泰凌醫藥(01011.HK)上半年錄得虧損淨額2820萬元
格隆匯8月31日丨泰凌醫藥(01011.HK)公佈,截至2022年6月30日止六個月,集團整體收益增加約人民幣930萬元至約人民幣1.205億元,相比2021年同期則約為人民幣1.112億元。於回顧期間,經營溢利減少約人民幣2070萬元至約人民幣760萬元,相比2021年同期的經營溢利則為人民幣2830萬元。集團於回顧期間錄得虧損淨額約人民幣2820萬元,相比2021年同期則約為虧損淨額約人民幣360萬元。
集團的中樞神經系統領域的主要產品為舒思(通用名:富馬酸奎硫平片),是集團首個自主研發、生產、銷售的產品。舒思主要用作治療精神分裂症和雙相情感障礙的躁狂發作,是非典型抗精神病的一線用藥。舒思自2003年上市銷售逾十五年,已擁有強大的品牌效應,得到臨牀醫生和市場的廣泛認可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.